ADVERTISEMENT

New Science

BPGbio: Fusing Patient-Driven Innovation With Causal AI

Biotech BPGbio applies causal AI to generate insights from samples from what the CEO says is one of the world's largest biobanks. With several promising late-stage programs, its platform seems to be yielding fruit.

Neurodegenerative Disease Investment: Shifting Paradigms Beyond Amyloid And Tau

Companies are exploring new mechanisms of action beyond traditional amyloid and tau and both investors and big pharma are willing to make deals when the science is compelling, panelists at Biotech Showcase said.

In Search Of Rare Disease Treatments, Nonprofits Can Lead the Charge

Nonprofits are finding new ways to address market gaps and develop treatments for rare diseases with little commercial attraction.

Artiva Leverages Unmodified NK Cells To Challenge CAR-T Paradigm

Artiva Biotherapeutics is hoping its NK cell therapy approach, which uses un-engineered cells, will prove effective in both oncologic and autoimmune indications and safe enough to be given in the community setting.

Podcast: How Fauna Bio Gleans Therapeutic Insights From Animals

In Vivo speaks with Ashley Zehnder, CEO of Fauna Bio, a company using AI to identify drug targets based on natural disease resistance in animals.

Podcast: The Future Of Immunotherapy

In this episode of the In Vivo podcast, Harvard immunologist and co-founder of early-stage biotech Corner Therapeutics, Jonathan Kagan, talks about harnessing the power of the innate immune system by weaponizing dendritic cells and creating immunotherapies that are safer and more durable.

ADCs, New Modalities High On Korea State Fund’s Priorities

While oncology and discovery-stage assets accounted for the majority of R&D projects supported by a Korean state fund this year, new modalities such as ADCs and TPDs are emerging.

Kenvue Vaping Cessation Study: Nicorette QuickMist Provides ‘Significant And Fast’ Relief

Use of Kenvue’s Nicorette QuickMist nicotine replacement therapy device resulted in “statistically significant reductions in urges to vape as soon as 30 seconds and up to two hours after dosing compared with placebo,” according to a recently published study funded by the firm.

Tobacco Giant Philip Morris Sells Medical Device Business, Keeps Consumer Health Footprint

Philip Morris described a scenario of being essentially blacklisted by the health care sector and its CDMO partners as it threw in the towel on its £1.1bn acquisition of UK inhalation specialist Vectura. It agreed to offload the firm at a fraction of the initial cost.

Tobacco Giant Philip Morris Sells Medical Device Business, Keeps Consumer Health Footprint

Philip Morris described a scenario of being essentially blacklisted by the health care sector and its CDMO partners as it threw in the towel on its £1.1bn acquisition of UK inhalation specialist Vectura. It agreed to offload the firm at a fraction of the initial cost.